Study Investigating STA363 Compared to Placebo in Patients With Chronic Discogenic Low Back Pain
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a phase IIb, prospective, multi-country, multicenter, randomized, double-blind,
placebo-controlled, parallel group study to investigate the efficacy, safety and
transformation of NP following single intradiscal injection of STA363 (lactic acid) into one
or two IVDs compared to placebo for the treatment of discogenic low back pain. This study
will be conducted in Russia, Spain and the Netherlands.